ContraVir Strikes Deal With Rival Early Stage Hep B Drug Developer
Executive Summary
ContraVir Pharmaceuticals Inc. is merging with competitor early stage hepatitis B drug developer Ciclofilin Pharmaceuticals to strengthen its pipeline offering in antivirals.